Literature DB >> 8627064

Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci.

P Van der Auwera1, N Pensart, V Korten, B E Murray, R Leclercq.   

Abstract

Changes in fecal flora were evaluated in 22 healthy volunteers administered oral vancomycin or teicoplanin in 1989-1991 in Belgium. Evaluation of 5 colonies per subject revealed no glycopeptide-resistant enterococci in the predominant flora before glycopeptide administration; however, large numbers (mostly Enterococcus faecium) emerged by the end of the study in 14 (64%) of the subjects. Pediococci and lactobacilli also increased in number. In 1992, 40 healthy volunteers and 33 cancer patients were evaluated by plating stool samples directly onto selective media containing vancomycin; low numbers of vancomycin-resistant enterococci (< 50 cfu/g) were found in 11 (28%) of the 40 and 4 (12%) of the 33 samples, respectively. DNA restriction fragment length polymorphism analysis showed that most isolates were different, but all contained vanA in Tn1546-like elements. These results indicate that vanA and Tn1546-like elements were common in Belgium as early as 1989 and that community-based individuals in that location likely form a major reservoir for glycopeptide-resistant enterococci.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627064     DOI: 10.1093/infdis/173.5.1129

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  60 in total

1.  Molecular epidemiology of vancomycin-resistant Enterococcus faecium in a large urban hospital over a 5-year period.

Authors:  W E Bischoff; T M Reynolds; G O Hall; R P Wenzel; M B Edmond
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  [Effects of restrictions on use of vancomycin in a German university hospital].

Authors:  T Glück; H J Linde; E Wiegrebe; N Lehn; M Reng; J Schölmerich
Journal:  Med Klin (Munich)       Date:  2000-02-15

Review 3.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 4.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

5.  Heterogeneity in the vanB gene cluster of genomically diverse clinical strains of vancomycin-resistant enterococci.

Authors:  K H Dahl; G S Simonsen; O Olsvik; A Sundsfjord
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

6.  From vanA Enterococcus hirae to vanA Enterococcus faecium: a study of feed supplementation with avoparcin and tylosin in young chickens.

Authors:  B Robredo; K V Singh; F Baquero; B E Murray; C Torres
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

7.  An Update on the Emergence of Glycopeptide Resistance in Enterococci.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

8.  Prevalence of vancomycin-resistant enterococci in fecal samples from hospitalized patients and nonhospitalized controls in a cattle-rearing area of France.

Authors:  K Gambarotto; M C Ploy; P Turlure; C Grélaud; C Martin; D Bordessoule; F Denis
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

9.  Molecular diversity and evolutionary relationships of Tn1546-like elements in enterococci from humans and animals.

Authors:  R J Willems; J Top; N van den Braak; A van Belkum; D J Mevius; G Hendriks; M van Santen-Verheuvel; J D van Embden
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

10.  Lactobacillus species identification, H2O2 production, and antibiotic resistance and correlation with human clinical status.

Authors:  A Felten; C Barreau; C Bizet; P H Lagrange; A Philippon
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.